目的 应用安罗替尼联合替吉奥三线治疗晚期非小细胞肺癌，观察疗效和安全性?方法 二线治疗后进展的晚期非小细胞肺癌患者45例，以随机表法分为治疗组与对照组，治疗组22例，对照组23例，治疗组采用安罗替尼联合替吉奥治疗，对照组采用安罗替尼单药治疗?结果 治疗组的客观缓解率和疾病控制率分别为18.18%和81.82%，对照组的客观缓解率和疾病控制率分别为8.70%和73.91%，无明显差异(P>0.05)?两组KPS评分治疗后均较治疗前有所升高，但组间无明显差异(P>0.05)?治疗组主要不良反应为骨髓抑制?皮肤“,”Objective To investigate the efficacy and safety of anlotinib plus S-1 as thirdly-line treatment in patients with advanced non small cell lung cancer (NSCLC). Methods Forty-five patients with advanced NSCLC after second-line treatment were randomly divided into treatment group and control group， 22 cases in the treatment group and 23 cases in the control group. The treatment group was treated with anlotinib combined with S-1. The control group was treated with anlotinib. Results After treatment， the response rate and the disease control rate were 18.18% and 81.82% in the treatment group， while the response rate and the disease control rate were 8.70% and 73.91% in the control group， but there was no significant difference between the groups. After treatment， the KPS score was significantly higher than those before treatment in both groups， but there was no significant difference between the groups. The most common adverse events were hematological toxicity， skin hyperpigmentation，hand-foot syndrome in the treatment group. The most common adverse events were hand-foot syndrome， hypertension， mucositis oral in the control group， but there was no significant difference between the groups. Conclusion The efficacy of anlotinib combined with S-1 in thirdly-line treatment of advanced NSCLC was higher than that of anlotinib alone， and the adverse events were controllable in both groups.